Palo Alto-based Midi Health has successfully raised $100 million in a Series D funding round, elevating the women’s telehealth company to a valuation exceeding $1 billion. This funding round was led by Goodwater Capital, with participation from new investors Foresite Capital and Serena Ventures. Existing investors, including GV, Emerson Collective, McKesson Ventures, Advance Venture Partners, and Felicis Ventures, also contributed to the round.
Addressing Women’s Health Needs
Founded with the mission to close significant gaps in women’s healthcare, Midi Health aims to provide comprehensive services to women navigating various health challenges. Every year, approximately two million women in the United States enter menopause, and untreated symptoms are estimated to cost the economy billions in medical expenses and lost productivity.
“This is validation for the movement we’re leading to provide women with better healthcare,” stated Joanna Strober, co-founder and CEO of Midi Health. “Women’s health has been treated like an afterthought for too long. This funding gives us the resources to rewrite that story at scale.”
Innovative AI Solutions for Patient Care
Under the leadership of Strober, Midi Health offers accessible, insurance-covered healthcare services across all 50 states. The company’s innovative AI engine enhances its offerings in three key areas:
1. **Personalising the experience**: AI-driven chart analysis allows for tailored care journeys, enabling faster and more accurate diagnoses.
2. **Streamlining operations**: Automation enhances efficiency in scheduling, triage, and documentation processes.
3. **Improving outcomes**: Midi leverages one of the largest datasets in women’s health to drive research and refine clinical protocols.
Currently, Midi Health collaborates with insurers that cover over 45 million women. The platform records more than 25,000 patient interactions each week, providing coordinated care across various medical specialties, including OB-GYN, internal medicine, cardiology, endocrinology, and dermatology.
The integration of AI not only aids in clinical decision-making but also personalises care experiences, reducing the administrative workload for healthcare providers. By harnessing extensive datasets, Midi is positioned to continually enhance care protocols and improve patient outcomes.
The company reports that its care model is yielding significant results. It has achieved higher adherence to cancer screenings and lower overall costs compared to similar patient demographics. Additionally, improvements have been noted in critical health indicators, such as A1c and LDL levels, demonstrating the effectiveness of its approach to women’s healthcare.
As Midi Health continues to scale, it remains focused on transforming how women access and engage with healthcare services, ensuring that their specific needs are met with the attention and respect they deserve.
